AKTS

Aktis Oncology, Inc. is a clinical-stage oncology company. The Company is focused on expanding the potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The Company’s proprietary mini-protein radio conjugate platform aims to safely confer efficacy to a range of patient populations. Its mini-protein radio conjugates are designed to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors with high tumor penetration and prolonged retention, while being rapidly cleared from normal organs and tissues to minimize systemic radiation exposure. Its pipeline includes AKY-1189 and AKY-2519. AKY-1189, is targeting Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, colorectal cancer and cervical cancer. AKY-2519 targets B7-H3 expressing solid tumors, such as prostate, lung and breast cancers.